STOCK TITAN

Cocrystal Pharma to Present at the H.C. Wainwright 6th Annual Israel Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

– Live video webcast with the Cocrystal management team, on Thursday, November 12th at 12:00 PM EST –

BOTHELL, WA, Nov. 06, 2020 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ: COCP), (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel antiviral therapeutics, today announced that the Cocrystal management team, will present at the H.C. Wainwright 6th Annual Israel Conference on Thursday, November 12, 2020 at 12:00 PM EST.

In addition to the presentation, management will also be available to participate in virtual one-on-one meetings with qualified members of the investor community who are registered to attend the conference.

A live video webcast of the presentation will be available on the IR Calendar page of the Investors section of the Company’s website (cocrystalpharma.com). The video webcast replay will be made available two hours following the event.

About Cocrystal Pharma, Inc.

Cocrystal Pharma, Inc. is a clinical stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, SARS-CoV-2 virus, hepatitis C viruses, and norovirus. Cocrystal employs unique, proprietary, structure-based technologies and Nobel Prize winning expertise to create first- and best-in-class antiviral drugs. For further information about Cocrystal, please visit www.cocrystalpharma.com.

Investor and Media Contact:

JTC Team, LLC
(833) 475-8247
COCP@jtcir.com

###

Cocrystal Pharma, Inc.

NASDAQ:COCP

COCP Rankings

COCP Latest News

COCP Stock Data

19.33M
7.11M
30.03%
6.72%
0.05%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
BOTHELL

About COCP

cocrystal (otcqb:cocp) is a pharmaceutical company seeking to discover novel antiviral therapeutics as treatments for serious and/or chronic viral diseases. cocrystal employs unique technologies and nobel prize winning expertise to create first- and best-in-class antiviral drugs. these technologies, including our nucleoside chemistry expertise and market-focused approach to drug discovery are designed to efficiently deliver small molecule therapeutics that are safe, effective and convenient to administer. the company has identified promising, preclinical stage antiviral compounds for the unmet medical needs including hepatitis, influenza and norovirus infections. cocrystal has previously received strategic investments from teva pharmaceuticals, opko health (opk), dr. raymond schinazi, brace pharmaceutical, llc, and the frost group.